ArticleBMC cancer2026
Isatin-mediated inhibition of the PI3K/AKT/EMT signaling axis confers antitumor efficacy in Ehrlich solid carcinoma-bearing mice.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances, detailed insight into cancer's biological mechanisms remains needed. Isatin, an indole-1 H-2,3-dione, is an attractive agent for new drug discovery. Here, the anticancer efficacy and potential toxicity of isatin in combination with doxorubicin (Dox) in a mouse Ehrlich solid carcinoma (ESC) model were examined by modulating the PI3K/AKT/EMT pathway. Five groups of fifty female mice were prepared: negative control, positive ESC-bearing mice, isatin-treated ESC group, Dox-treated ESC group, and isatin and Dox combination-treated ESC group. Treatments began after tumor formation. Inflammatory markers, kidney and liver enzyme activities, and EMT markers levels (vimentin and E-cadherin) were assessed by ELISA. HIF 1 α, NF-κB, PI3K, AKT, MMP2, and MMP9 gene expression was evaluated using qRT-PCR. Protein expression of MMP-9 and E-cadherin was assessed by IHC. Compared with the positive control, the combined treatment reduced tumor growth by 51%. Additionally, combined treatment showed a significant increase in the amount of necrotic tissue. Mechanistically, isatin exerted its therapeutic effect by increasing anti-inflammatory (IL-10) cytokine levels and suppressing pro-inflammatory (IL-6) cytokine levels, along with reductions in HIF-1α, NF-κB, PI3K, AKT, MMP2, and MMP9 mRNA levels. Also, a combined group of isatin and Dox showed reduced vimentin levels and elevated E-cadherin levels by ELISA. Co-administration of isatin and Dox significantly increased E-cadherin expression and attenuated MMP-9 expression compared with the untreated group, as assessed by IHC. Our results indicate that isatin, in combination with doxorubicin, exerts a synergistic anticancer effect against ESC, offering a promising therapeutic approach to enhance treatment efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.